Introduction
It is generally assumed that treatment of hypertension should restore the blood pressure (BP) profile towards that of a normotensive individual over 24 h. Lowering BP during day and night and prevention of the excessive increases that occur with awakening and arising may reduce (or prevent) cardiac hypertrophy, reduce silent ischaemic episodes and the increased prevalence of sudden death, myocardial infarction and cerebrovascular accidents that occur more frequently at the time of the acute BP rise in the early morning. [1] [2] [3] [4] We discuss here the relationship of this requirement to the concept of the trough to peak (T:P) ratio for antihypertensive drugs.
Once a day therapy
Antihypertensive drugs are usually developed to be taken once a day to improve compliance in treatment of a life-long disorder. 5, 6 In pre-registration clinical evaluation, drugs are usually taken at around 8.00 am and the titration of the drug to an effective dose is based on the BP measured pre-dose. If reduction of BP can be shown 24 h post dose, this may have been obtained at the expense of an excessive drop in BP at the time of peak drug effect. 7 To identify and prevent such problems the concept of T:P ratio was introduced by the United States Food and Drug Administration 7 with a general requirement that it should be at least 0.5 to 0.66. However, the T:P ratio should never be considered in isolation. The important information is the peak fall in BP and the percentage that persists at the time of the next dose (Table 1) .
Initially, measurement and calculation of the ratio appeared simple. 7, 8 BP was measured at the clinic prior to taking medication. The drug was given and BP was measured at the time of peak effect. Values were subtracted from corresponding values during a Correspondence: Dr T Morgan, Department of Physiology, University of Melbourne, Parkville, Australia Received 2 February 1997; revised and accepted 7 July 1997 placebo run-in period. Trough and peak falls were measured and the T:P ratio calculated. Correction for placebo effect in a parallel group design could be applied, although ideally the placebo correction should come from a randomised crossover study of placebo and drug. The advent and widespread use of ambulatory BP monitors changed the situation. More searching questions about how the ratio should be measured were raised. Should it be measured in all patients or is it only informative in responders to therapy? 9 Should it be measured for a drug or each dose of a drug? 10 Should it be calculated for individual patients and a mean (or median) obtained or should it be calculated from group means?
11 Further questions related to the definition of peak and trough responses. Inappropriate definitions arising from this process have led, in our view, to an underestimation of the T:P ratio for many drugs. This has been highlighted by a recently-published meta-analysis. 
Twenty-four hour ambulatory BP monitoring (ABPM)
Before discussing definitions of trough and peak responses it is important to consider certain limitations of ABPM. When a monitor is first applied to a patient the values in the first 60-90 min are high 13, 14 and closer to the value measured by clinical sphygmomanometry ( Table 2) . Whether this occurs with subsequent ABPM has not been rigorously documented but in our experience it does, though [14] [15] [16] there is a significant placebo effect with 24-h ABPM. 17, 18 Though relatively small in an absolute sense (systolic 2 mm Hg, diastolic 1.5 mm Hg), in the context of a total change of 8-10 mm Hg with monotherapy the effect may have an important impact on the T:P ratio. Placebo effects are not uniform throughout a 24-h period, with most change occurring by day. 14, 17 Finally, and possibly most importantly, the changes in ambulatory BP with monotherapy when corrected for placebo are usually 10 mm Hg or less. 17, [19] [20] [21] [22] [23] This contrasts with mean changes of 20 mm Hg or more associated with arising and awakening in normotensive groups and even greater changes in individual people with hypertension. 10, 13, 20 Unless interaction between these effects is avoided, spurious results will be obtained (Table  2) as the spontaneous variations in BP are more marked than the drug effect.
Peak response
The availability of a large number of BP recordings at different time intervals suggested that the time of maximum BP fall after a drug in an individual could be easily identified. Peak response was defined as the largest fall in BP compared to a placebo day. Ideally the placebo and treatment days should be randomised, but for practical reasons a sequential approach has usually been followed. 10, 20, 24 This definition of peak effect inevitably overestimates the true effect unless physical activity or other activities which affect random fluctuations in BP are identical on both study days. Unless the experiment is rigorously controlled 10 this is extremely unlikely. On the placebo day a high value may be recorded due to altered activity or an artefact in BP recording. Unless the same effect occurs at the same time on the treatment day this leads to an artificially large fall in BP. If a patient is studied with two placebo and one active treatment day the measured time of peak response may vary widely. Figure 1 shows peaks from such a study at both 4 and 8 h after dosing. Thus the extent and timing of the peak effect is determined by responses on the placebo day.
The 24-h mean of ambulatory BP monitors is relatively constant but the variation from hour to hour is high. The variance allows small differences to be measured only when the mean is derived from 12 to 16 recordings 24, 25 (ie, a 3-4 h time interval). In a study by Omboni et al, 26 the peak hourly effect of 9/6 mm Hg was seen with placebo when there was no effect of placebo on mean 24-h BP. This illustrates clearly the artificiality of this peak definition, especially since this 'placebo peak response' is unfortunately close to the mean fall seen with monotherapy ( Table 2) . The above consideration argues in favour of using a standard time to define peak responses.
Various approaches have been made to minimise or correct for this random variation, namely hourly BP means rather than specific individual BP, Fourier transformation of data, smoothing procedures, moving averages and extending the time interval around the maximum effect to 2, 3, 4 or 6 h. 11, 17, 26, 27 The topic has been extensively discussed by Parati, Zanchetti and Mancia. [24] [25] [26] [27] From their analysis we believe that a 4-h mean should be recommended rather than a shorter period of 2 h. 11, 26 Their data and that of others contradicts the use of a short time Figure 1 Hourly mean BP in a patient who received amlodipine 10 mg daily and placebo on two occasions, and had an ABPM performed after 1 month on either placebo (twice) or amlodipine (unpublished clinic data). The monitor was placed on at 8.00 am and medication taken. BP was measured 4 times/hour between 6.00 am and 10.00 pm and twice an hour from 10.00 pm until 6.00 am. The patient left the clinic on day 1 at about 9.00 am and returned the following day at 10.00 am. The values plotted for 9.00 am and 10.00 am are those measured on the second day. On the first placebo and active treatment days the patient arose at about 6.00 am. On the second placebo day the patient arose after 7.00 am. When the two placebo days are compared there is an apparent 'peak' fall at noon or 4.00 pm depending which placebo day was taken as baseline (A, B). When compared with the first placebo day the maximum fall in BP occurred at about 4.00 pm (D), 8 h after medication was taken. When compared with the second placebo day the peak fall in BP was about noon (C), 4 h after medication was taken. interval (Table 3) . Furthermore we see no necessity for the defined period to relate to a 'potentially, almost certainly falsely' high peak response and recommend that peak response should be the average BP 3-6 h after dosing compared to a placebo day. Most once-daily antihypertensive drugs reach their peak plasma concentration and have their greatest effect on BP during this period.
This standardised time for peak effect is appropriate for most drugs with chronic administration but may need to be modified under certain circumstances. Thus captopril and lisinopril, which do not require conversion to the active drug, may have a peak effect starting within 1 h of administration. For drugs with an early peak effect, the first 60-90 min of the ABPM should not be used to generate data 14 because of the spurious elevation of BP related to application of the monitor or clinic attendance. If a drug planned for once a day use does not maintain close to its maximal response for 4 h it is highly unlikely to persist for 24 h. However, individual data inspection is essential, and if the 'peak fall' occurred due to an acute drop on the active day then the data would need to be reviewed. There is no absolute objection to a 2 h interval provided this was over a fixed time post dose ( Table 3 ).
Drugs that have had major modification of their delivery system (eg, nifedipine GITS/OROS, diltiazem SR) may also have a different time course of effect. This usually applies to the first dose and is less of a problem during chronic administration.
Trough response
If the definition of peak response is the 'greatest fall' in BP, a possible definition of trough response is the 'smallest fall' in BP during the dosing interval. The problems of measurement described above apply equally to this definition, which would obviate a T:P ratio equal to 1.0. Most would be less than 0.3 and many 0.0. It has been stated that trough effect is easy to determine, 10, 28 being merely the BP at the end of the dosing interval. However, this is not as simple as it appears. If the patient has come to the clinic to have the ABPM removed, BP in the last one or two recordings reflect the clinic environmental effects and not the true BP. This effect causes the true trough effect to be underestimated, leading to an underestimate of the ratio. Even if precise timing is used on both placebo and treatment days a major error is likely to occur as placebo has a much greater effect on clinic than on ambulatory pressure.
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If a smoothing or averaging technique is used there is another problem. If the drug is taken at 8.00 am, BP recorded in the previous 2 h may include readings when the person was still in bed. Thus absolute BP on the placebo day at the time trough response is calculated may be lower than peak BP effect. Falls in BP depend partly on the baseline level. Thus even if blood level and effect are constant, the T:P ratio could be less than 1.00. This appears to be confirmed in some studies with nifedipine GITS and with trandolopril, both of which provide a consistent blood level but ratio values below 1.00 have been reported. 19, 27, 29, 30 A further complication is relevant when the drug is taken in the morning. If the time of awakening and arising is different on the two days (active and placebo), spurious results can be obtained that are related to the usual rise in BP with rising. This physiological change is 20-25 mm Hg or more and is much greater than the likely drug effect. BP does not rise gradually with awakening and arising but is relatively sudden. 31 Pooled data appear to show a gradual rise but this is due to different individual times of awakening. Likewise individual ABPM data using 30-or 60-min averages show a gradual BP change, but with shorter periods of collection the time of awakening is usually obvious. Thus spurious responses are very easy to obtain. An example of the magnitude of this effect is provided in a report of the APTH study 32 which is discussed below. To avoid these problems we suggest that if an ABPM is applied and the drug is taken at 8.00 am or 9.00 am, the trough effect must not be defined 22-24 h after dosing. Rather, it should be defined as BP measured in a 2 h period starting 30 min after awakening and arising, taking care that the trace does not contain pressures influenced by 'clinic contamination'. If the time of rising varies, we would use the same time interval starting on the day the person rose latest. In studies on amlodipine [33] [34] [35] [36] [37] in which the drug has been taken at different times, the values for T:P are lower when medication was taken at 8.00 am or earlier, supporting this concept of contamination.
Suggested procedure
To determine the T:P ratio and obtain maximal information about a drug's effect on BP, we suggest the following (Table 4) . We assume that medication is taken at about 8.00 am as is common in clinical practice and clinical trials. The procedure requires a monitor to be worn for 27 h on both placebo and active days. Ideally the placebo day should be randomised and not sequential. The rationale for adjusting with a parallel group of patients receiving placebo is open to question. If this procedure is undertaken but the monitor is worn for 30 h and medication is not taken (or is ideally replaced by placebo) on the second day, the acute effect of a drug The time of peak effect may be modified if the known kinetics produce a peak effect outside the standard time interval or the drug is presented in a controlled delivery system giving prolonged 'peak' effects.
in a person on chronic therapy is available by comparing the response at hours 3, 4 and 5 with hours 27, 28 and 29 after dosing. This procedure corrects for circadian and placebo effects and requires only one ABPM. It does not give the fall in BP compared to placebo, but an approximation of this may be obtained if the monitor is continued over 48 h. 38 Alternative procedures can be suggested. One difficulty relates to the application and removal of the APBM at the clinic. If a patient took their medication at 9.00 am an alternative procedure (Table 5) is possible. This requires an ABPM to be worn for 24 h and avoids problems related to time of application and removal, but does require the person to wait for 2 h after arising before taking their medication and relies on the patient accurately taking and recording the time of medication.
T:P ratio with evening medication
The above two examples relate to medication taken in the morning. How should T:P be measured if the drug is taken at night? The problems associated with this are well illustrated in the APTH study, 32 in which medication was taken between 7.00 and 11.00 pm. The peak effects were at 9.5 (systolic) and 13 h (diastolic) after dosing and were large (41/31 mm Hg). It is likely that this was an artefact related to the time of awakening and arising being different on the two study days. To evaluate the T:P ratio of a drug taken at night using the maximum fall as definition of peak response is virtually impossible unless the patient follows exactly the same routine on each occasion. Even if this is adhered to there are still difficulties as the BP at the time of maximum effect is lower than if the drug is taken in the morning because of the normal nocturnal fall. The expected drug effect is thus also lower. This problem may be overcome by using percentage rather than absolute falls in BP. Utilisation of a fixed time definition for peak effect will prevent an artificial greater response which would be obtained if the greatest response in 12 h after administration is used. The 12-h interval includes the rising period and unless these are synchronised the physiological alterations in BP are much greater than the response to the drug, and cause artefactual changes in BP which will affect measurement of the ratio.
Conclusion
The commonly used definitions for trough and peak response may lead to a gross underestimate of the T:P for many drugs. Drugs with a long half-life or with steady blood concentrations caused by special delivery systems are frequently reported to have a T:P ratio less than 1.00 using ambulatory monitors, but values are higher when clinical measurements are used. The T:P ratio of a drug is useful to assist in selection of the drug, its dose and the method and time of administration in management of individual patients. For a drug with a T:P ratio of approximately 0.7 or above with relatively small variance, the patient's response of BP can be titrated at time of either trough or peak effect and full 24-h control of BP may be assumed. 20, 39 If the ratio is Ͻ0.7, it should be titrated at trough, except that the possibility of excessive peak fall in BP needs to be checked. Alternatively, drugs may be administered at night, but important factors related to the chronobiology of BP and chronotherapeutics may intrude. T:P ratio data achieved with morning administration may not apply to night-time dosing. 21, [40] [41] [42] T:P ratio may not represent the ideal guide to management of hypertensive patients. Rather it helps to determine whether BP is normalised during both day and night and whether the excessive acute rises seen in hypertensive individuals have been suppressed. Unfortunately the absolute changes of BP represented in the ratio and which optimally affect outcome are as yet unknown.
